SCHEMBL4144089

SCHEMBL4144089

CC(C)(C)OC(=O)c1ccsc1NC(=O)C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.45
▸ POLB P06746 1/20 0.44
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ MAPK8 P45983 2/20 0.41
▸ CNR2 P34972 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ PTPN2 P17706 1/20 0.39
▸ PTPRB P23467 1/20 0.39
▸ PTPN6 P29350 1/20 0.39
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10627226 0.82 PTK2 (0.50) KMT2AMEN1SMN1; SMN2KDM4EPOLB
SCHEMBL4141410 0.79 PTPN2 (0.62) KMT2AMEN1SMN1; SMN2KDM4EPTK2
SCHEMBL5425994 0.78 ALDH1A1 (0.35) KMT2AMEN1SMN1; SMN2KDM4EMAPK8
SCHEMBL1703720 0.78 KMT2A (0.66) KMT2AMEN1SMN1; SMN2KDM4EPOLB
SCHEMBL5478399 0.77 PTK2 (0.63) KMT2ANPC1RAB9APTK2MAPK8
SCHEMBL27780906 0.74 KDM4E (0.42) KMT2AMEN1SMN1; SMN2KDM4EPOLB
SCHEMBL4156818 0.74 PDK1 (0.51) KMT2AKDM4EPOLBMAPT
SCHEMBL4150055 0.73 ABCC1 (0.40) KMT2AMEN1KDM4ETDP1ALDH1A1
SCHEMBL1703501 0.73 PTPN2 (0.58) KMT2AMEN1SMN1; SMN2KDM4ENPC1
SCHEMBL162737 0.72 ALDH1A1 (0.37) KMT2AMEN1SMN1; SMN2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 — — US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 — — EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 — — WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 — — US disclosed
US-20070249670-A1 Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof SMITHKLINE BEECHAM CORPORATION (US) 2007-10-25 — — US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 — — EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL KMT2A 3189/4885MEN1 46/4885SMN1; SMN2 155/4885
US-20070249670-A1 Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof PYGM, PYGL, GYS1 KMT2A 4148/4885MEN1 4256/4885SMN1; SMN2 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback